A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Previously Treated Non Small Cell Lung Cancer

In brief

A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell Lung Cancer Patients

Key facts

Study ID

NCT02087176

Run by

AstraZeneca

People needed

48

Starts

2014-03-01

Expected to finish

2015-05-01

Last updated by the study team

2016-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of informed consent prior to any study specific procedures
• Histologic or cytologic diagnosis of advanced NSCLC, excluding large cell neuroendocrine, and mixed NSCLC/small-cell histologies
• Failure of one prior platinum-based doublet treatment for advanced NSCLC (either due to progressive disease or toxicity)
• Measurable disease as measured by Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• Mandatory availability of tumour tissue (archival or fresh if archival is not available) for TP53 testing
• Male or female ≥18 years-of-age
• Subjects may have received radiation for palliation prior to starting study treatment if they have recovered from the side effects of such therapy
• Absolute neutrophil count (ANC) ≥1500/μL
• Haemoglobin (Hgb) ≥9 g/dL
• Platelets ≥100,000/uL
• Adequate liver function defined as:
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal limits (WNL) or ≤2.5 x upper limit of normal (ULN), if liver metastases are present
• Serum bilirubin WNL
• Adequate renal function
• Ability to swallow oral medication
• Fertile male subjects willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stops
• Female subjects who are not of childbearing potential and fertile female subjects of childbearing potential who agree to use adequate contraceptive measures
• Predicted life expectancy ≥12 weeks
• Willingness and ability to comply with study and follow-up procedures
• Ability to understand the investigational nature of this study and give written informed consent
• Most recent chemotherapy ≤21 days or have not recovered from the side effects > Grade 1.
• Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of AZD1775
• Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting AZD1775 or has not recovered from side effects of such therapy
• Major surgical procedures ≤28 days of beginning AZD1775, or minor surgical procedures ≤7 days

Where it is running

• Research Site — Birmingham, Alabama, United States
• Research Site — Scottsdale, Arizona, United States
• Research Site — Fayetteville, Arkansas, United States
• Research Site — Englewood, Colorado, United States
• Research Site — Orlando, Florida, United States
• Research Site — Wichita, Kansas, United States
• Research Site — Louisville, Kentucky, United States
• Research Site — Durham, North Carolina, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Pittsburgh, Pennsylvania, United States
• Research Site — Nashville, Tennessee, United States
• Research Site — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.